Denosumab
Links shared publicly online about this topic
Denosumab (Xgeva) Not Approved For Metastasis Prevention
medicalnewstoday.com — “Amgen's application for expanded indications for denosumab (Xgeva) were turned down by the FDA (Food and Drug Administration) - the expanded indications were to include bone metastases prev” View full resource at medicalnewstoday.com
Most Recently Shared on April 28, 2012 at 6:05 pm By:
Denosumab (Xgeva) Not Approved For Metastasis Prevention http://t.co/vGNxVySp #cancer
New Biologic Osteoporosis Drugs Denosumab, Odanacatib in the Works
webmd.com — “Two experimental osteoporosis drugs -- denosumab and odanacatib -- are getting attention from bone experts -- and may become the first biologic drugs to treat osteoporosis.” View full resource at webmd.com
Most Recently Shared on September 18, 2008 at 8:35 pm By:
WebMD Health News New Osteoporosis Drugs in the Works: Two experimental osteoporosis .. http://tinyurl.com/5458l6
Development Of Prostate Cancer Bone Metastasis Delayed By Denosumab
medicalnewstoday.com — “An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer. The stud” View full resource at medicalnewstoday.com
Most Recently Shared on November 16, 2011 at 10:06 am By:
Development Of Prostate Cancer Bone Metastasis Delayed By Denosumab http://t.co/1LkhIR3M #prostate
ingentaconnect Population Pharmacokinetic Analysis of Denosumab in Patients with...
ingentaconnect.com — “ingentaconnect Population Pharmacokinetic Analysis of Denosumab in Patients with...” View full resource at ingentaconnect.com
Most Recently Shared on March 17, 2012 at 10:39 am By:
Drugs and Devices OW OW Health
Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours: (Source: C... http://t.co/O5V10rVM
FDA approves denosumab for treatment of postmenopausal osteoporosis
endocrinetoday.com — “The FDA today approved denosumab, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. Den” View full resource at endocrinetoday.com
Most Recently Shared on June 2, 2010 at 6:35 pm By:
#FDA approves #denosumab for treatment of postmenopausal #osteoporosis http://ow.ly/1T55c
FDA Does Not Give Denosumab Priority Review
fdanews.com — “The FDA is giving Amgen’s denosumab a 10-month review period although the company requested priority review for its BLA.” View full resource at fdanews.com
Most Recently Shared on February 24, 2009 at 1:14 pm By:
eyeonfda Pharma and Health Lawyer
FDA Does Not Give Amgen's Denosumab Priority Review - http://is.gd/kEVV
FDA approves denosumab to increase bone mass
endocrinetoday.com — “The monoclonal antibody denosumab has received FDA approval to improve bone mass among patients at high risk for fracture who receive androgen d” View full resource at endocrinetoday.com
Most Recently Shared on September 19, 2011 at 8:14 pm By:
#FDA approves #denosumab to increase bone mass http://t.co/w1xR9xqe
Denosumab: A Review of Its Pharmacology and Clinical Implications
onclive.com — “It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.” View full resource at onclive.com
Most Recently Shared on August 18, 2011 at 8:05 pm By:
Denosumab: A Review of Its Pharmacology and Clinical Implications http://t.co/VL8ZCY0
Pharmacy Europe - Amgen seeks new denosumab approval
pharmacyeurope.net — “Pharmacy Europe, daily news for pharmacists, hundreds of clinical and best practice articles, online comment and video presentations.” View full resource at pharmacyeurope.net
Most Recently Shared on May 17, 2010 at 4:38 pm By:
Drugs and Devices OW OW Health
Amgen seeks new denosumab approval: Biotechnology giant Amgen is seeking US approval for the use of its osteoporos... http://bit.ly/c5wntq
Treatment Of Rare Type Of Bone Tumour: Promising Results With Denosumab
medicalnewstoday.com — “Denosumab is a targeted therapy to prevent bone loss. It stops progressive bone destruction and tumour spread in some patients with inoperable giant-cell tumour (GCT) of bone. An article published” View full resource at medicalnewstoday.com
Most Recently Shared on February 10, 2010 at 1:18 pm By:
Treatment Of Rare Type Of Bone Tumour: Promising Results With Denosumab http://mnt.to/3xqn #healthnews
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years
medicalnewstoday.com — “Postmenopausal females with osteoporosis or low bone mass who are on Prolia (denosumab) treatment were found to have continued increase in BMD (bone mineral density) for up to eight years, Amgen a” View full resource at medicalnewstoday.com
Most Recently Shared on September 19, 2011 at 6:05 am By:
Prolia (Denosumab) Maintains Menopausal Women's Bone Density For Over Eight Years http://mnt.to/3ZJM #menopause
Medicine and Technology [part of HCPLive]: Prolia (denosumab) approved by the FDA for the treatment of osteoporosis
medicineandtechnology.com — “Medicine and Technology [part of HCPLive]: Prolia (denosumab) approved by the FDA for the treatment of osteoporosis” View full resource at medicineandtechnology.com
Most Recently Shared on June 2, 2010 at 7:14 pm By:
Joseph Kim, MD, MPH Doctor and Physician
Prolia (denosumab) approved by the FDA for the treatment of osteoporosis http://bit.ly/ctuyuG
Amgen's Osteoporosis Drug Denosumab (Prolia) at FDA Panel - Health Blog - WSJ
blogs.wsj.com — “But several analysts said Amgen's experimental bone drug denosumab fared well enough to stay on track.” View full resource at blogs.wsj.com
Most Recently Shared on August 14, 2009 at 1:42 pm By:
Physician Assistants Health News Feed
Analysts react to FDA panel: http://tinyurl.com/p8dmla Amgen's future in Denosumab
Prolia (denosumab), Amgen Osteoporosis Drug, Advances in Europe - Health Blog - WSJ
blogs.wsj.com — “Amgen is betting its future on a single bone drug.” View full resource at blogs.wsj.com
Most Recently Shared on December 18, 2009 at 11:39 pm By:
Prolia (denosumab), Amgen Osteoporosis Drug, Advances in Europe - Health Blog - WSJ - http://shar.es/aDkeD
Amgen's Osteoporosis Drug Denosumab (Prolia) at FDA Panel - Health Blog - WSJ
blogs.wsj.com — “But several analysts said Amgen's experimental bone drug denosumab fared well enough to stay on track.” View full resource at blogs.wsj.com
Most Recently Shared on August 14, 2009 at 1:18 pm By:
Analysts React to FDA Panel: ‘It Wasn’t a Perfect Day for Amgen’ http://bit.ly/MQFNp
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Cancer News
The latest cancer news published daily. Articles from research centers, universities and prestigious journals.
-
WebMD_News
The leading source for trustworthy and timely health news and information.
-
MNT Prostate News
Advertisement
